Oxaliplatin-DNA adduct formation in white blood cells of cancer patients - Wikidata - awgldk - TriplyDB

Oxaliplatin-DNA adduct formation in white blood cells of cancer patients

Oxaliplatin-DNA adduct formation in white blood cells of cancer patients

http://www.wikidata.org/entity/Q36740632

about

Review of Cisplatin and oxaliplatin in current immunogenic and monoclonal antibody treatments Use of Accelerator Mass Spectrometry in Human Health and Molecular Toxicology Oxaliplatin: a review in the era of molecularly targeted therapy Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trial.Formation of cyclophosphamide specific DNA adducts in hematological diseases Kinetics of DNA adduct formation in the oral cavity after drinking alcohol.Time course of DNA adduct formation in peripheral blood granulocytes and lymphocytes after drinking alcohol.Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer.DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine.Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice.Review of Cisplatin and Oxaliplatin in Current Immunogenic and Monoclonal Antibodies Perspective.

P2860

Q28082382-834D4C0D-5EA6-4F36-9E1D-BD71F3FB2531 Q28818313-38619018-E742-4072-ACAF-39917797F7DD Q34541434-F90614C0-3EE9-4952-984F-BA58BC71218A Q35358778-9BDDB4B8-3007-4D5A-B545-F5AEEFEDD52A Q35478775-4693720A-AC43-4A46-8A68-C716565D3155 Q35870014-A07EED3B-2F9A-408D-9BAA-7D927E8C907F Q36055976-76CB8DAB-FDAD-4BE5-BB32-188C99DB43DF Q36817080-EFF814E0-3E99-4006-A865-74D96DAF0B01 Q37376421-D603F20A-6C53-4C6F-8FFE-A9E13B115484 Q37736567-136BCCE3-EAAD-41E8-9266-D6A6FB195134 Q38728212-F35F5DA7-B803-4EA6-8D4C-59B6FC72217B Q44242635-9ACB348A-34F8-4C89-B8DC-CB0FE0D3C89F

P2860

Oxaliplatin-DNA adduct formation in white blood cells of cancer patients

http://www.wikidata.org/entity/Q36740632

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Oxaliplatin-DNA adduct formation in white blood cells of cancer patients

@ast

Oxaliplatin-DNA adduct formation in white blood cells of cancer patients

@en

type

label

Oxaliplatin-DNA adduct formation in white blood cells of cancer patients

@ast

Oxaliplatin-DNA adduct formation in white blood cells of cancer patients

@en

prefLabel

Oxaliplatin-DNA adduct formation in white blood cells of cancer patients

@ast

Oxaliplatin-DNA adduct formation in white blood cells of cancer patients

@en

P1433

Q36740632-F661D50E-039D-40C8-B915-0CD970A2344E

P1476

Q36740632-EC2D4219-1FB0-4B91-87D6-3BF7368D069A

P2093

Q36740632-2FE27911-708B-4A32-A788-42B540D64DDC

Q36740632-63683368-408E-4ED3-BCE8-1E0D8ACFB795

Q36740632-7DBEF1F8-8228-4B36-8075-BCF8B2538582

Q36740632-9F733B2B-A1EF-46F2-BED5-6510E1A70DF6

Q36740632-CF230B53-D1ED-4ACA-8907-A239F80955B3

Q36740632-DFCCD05F-B9BC-4DEF-AAFF-ABA32ADA9D78

Q36740632-E5480C04-43CA-4543-A8BC-75F8B3936F8E

Q36740632-E68D2565-774E-4D9E-A1D6-B6098DAF08BD

Q36740632-EB1DAE09-FBBB-4C22-B5A1-37BF3F7D95E7

P2860

Q36740632-15945973-96F2-4873-86AE-CE633CD3343B

Q36740632-169BCB1D-705C-469F-B9B2-DC643C13E591

Q36740632-20D1D712-BF7F-4EE8-AFD3-E291AACCE1B6

Q36740632-243D9AC0-7937-4DCB-8C16-58EC6DF55A7F

Q36740632-2906A9EC-07BA-4E8E-A14B-F81DE155C82B

Q36740632-29731E04-1D97-4E97-83B6-66414203D143

Q36740632-2A7635F8-0EDF-4BE5-88B7-CA204841F7E7

Q36740632-3B2704D9-1346-4411-A2D0-E4ED67503795

Q36740632-429B0CC6-A54B-4581-9263-3392F908F84A

Q36740632-4835721E-32E4-4BEB-B3BF-0411D523119A

P2888

Q36740632-E94425B2-39B1-4365-8340-6D101B14B13A

P304

Q36740632-8B3F449C-23BA-415F-9D83-F7412EF7D60B

P31

Q36740632-8BB8F0AD-5314-49C8-A63C-EEA0295665E9

P356

Q36740632-E9C31FE9-DFDB-4D9C-B24B-35169B0A62D1

P407

Q36740632-703CE409-C7F5-4821-AEB5-1FF49BAC20D3

P433

Q36740632-B8B18D82-414B-45EA-A482-F5974B6D463D

P478

Q36740632-7B4FFB73-E473-4786-920B-A74D9544AC49

P577

Q36740632-594934FB-4388-48CB-8F2B-D6D2EFFB0B6F

P5875

Q36740632-627CCE60-3A18-403A-80BE-A7BF98770C06

P698

Q36740632-C6A6A561-7351-4F92-B304-E0FED8961916

P921

Q36740632-AFC7E625-E511-4EE6-A08A-24C06FED6BF4

P932

Q36740632-05E7ECC7-A422-4DED-BFBD-FD0623EADD4E

P356

P1433

British Journal of Cancer

P1476

Oxaliplatin-DNA adduct formation in white blood cells of cancer patients

@en

P2093

A C Pieck

http://www.w3.org/2001/XMLSchema#string

A Drescher

http://www.w3.org/2001/XMLSchema#string

D Strumberg

http://www.w3.org/2001/XMLSchema#string

G Weber

http://www.w3.org/2001/XMLSchema#string

J Messerschmidt

http://www.w3.org/2001/XMLSchema#string

K G Wiesmann

http://www.w3.org/2001/XMLSchema#string

M E Scheulen

http://www.w3.org/2001/XMLSchema#string

R A Hilger

http://www.w3.org/2001/XMLSchema#string

U Jaehde

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair

Adaptive intrapatient dose escalation of cisplatin in patients with advanced head and neck cancer.

Oxaliplatin-related side effects: characteristics and management.

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.

Oxaliplatin: pharmacokinetics and chronopharmacological aspects.

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures.

Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy.

DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells.

P2888

P304

1959-1965

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6604387

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5345061

http://www.w3.org/2001/XMLSchema#string

P698

18506148

http://www.w3.org/2001/XMLSchema#string

P921

P932

2441951

http://www.w3.org/2001/XMLSchema#string